news
CDK4/6 and PARP combo improves prostate cancer treatment
Researchers at VHIO have discovered a new way to overcome drug resistance in metastatic prostate cancer – by combining CDK4/6 inhibitors with follow-up therapies.
List view / Grid view
Kinases
news
Leukaemia cells hit hard by innovative dual-drug approach
Scientists have discovered a dual-drug therapy that dramatically increases leukaemia cell death, offering new hope for patients with acute myeloid leukaemia (AML). By combining SRC and MCL-1 inhibitors, this approach opens the door to more effective treatments.
news
The role of KDR in the survival of HTLV-1-infected T cells
KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1.
news
Finding the fundamental pathway in ALD pathogenesis
Liver-specific knockdown of TRPC3 enhanced alcohol's inhibitory effect on AMPK through a mechanism of Ca2+-dependent CaMKK2 activation.
news
Enzyme substrate mutations promote tumour growth
Using a newly developed algorithm and a validation study, US researchers find that cancer hijacks a class of enzyme mutations to fuel tumorigenesis.
news
Researchers discover clues on how cells control their volume
A new study from the University of Pittsburgh and Carnegie Mellon University may solve the puzzle of how cells control their volume.
news
Study reveals how molecular motor proteins are involved in malaria transmission
Scientists have made a breakthrough in how malaria parasites divide and transmit the disease, a major step forward in preventing one of the biggest killer infections in the world.
news
New research sheds light on what influences target protein binding time
The length of time that drug molecules attach to their target protein varies greatly and impacts the protein’s behaviour and drug efficacy. In a new study, scientists in Finland have identified some causal factors for this variance, with the hope it will bring clarity for drug developers.
webinar
Automating functional cell-based bioassays: assay reproducibility and performance for potency testing programmes
28 May 2021 | By Eurofins DiscoverX* and Tecan
In this on-demand webinar, we discuss how Eurofins DiscoverX’s off-the-shelf, MOA-based functional, cellular assays address these challenges, enabling drug discovery programmes up to late-stage development and market release.
whitepaper
Catalogue: Drug target reagents
5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.
webinar
Novel small molecule inhibitors of oncogenic SHP2 variants characterised by cellular target engagement
28 January 2021 | By Eurofins DiscoverX & Sanford Burnham Prebys Discovery
In this on-demand webinar industry experts discuss how the InCELL Pulse technology provides a valuable tool for the discovery and characterisation of novel SHP2 inhibitors.
news
Apilimod small molecule shows potent inhibition of SARS-CoV-2 in cells
Researchers have found the small molecules Apilimod and Vacuolin-1 inhibited the PIKfyve kinase in cells, preventing infection from Zaire ebolavirus and SARS-CoV-2.
whitepaper
Application note: A kinase inhibitor phenotypic screen using a multiplex T Cell activation assay
Modulating the TCR signaling pathway using biologics, small molecules or genetic engineering is highly relevant to many therapeutic areas including cancer immunotherapy, adoptive cell therapy, vaccine development and autoimmune disease.
news
Binding site of drug compound and tumour suppressor protein revealed
Using cyro-electron microscopy, researchers have imaged the binding site between a molecule and the tumour suppressor protein PP2A, enabling optimisation of the drug compound.
